Related references
Note: Only part of the references are listed.Bortezomib-resistant nuclear Factor-κB activity in multiple myeloma cells
Stephanie Markovina et al.
MOLECULAR CANCER RESEARCH (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-κB activation
Mizuho Hasegawa et al.
EMBO JOURNAL (2008)
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells
Teru Hideshima et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Ubiquitin-mediated activation of TAK1 and IKK
A. Adhikari et al.
ONCOGENE (2007)
Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis
H. Chen et al.
ONCOGENE (2006)
MLN120B, a novel IκB kinase β inhibitor, blocks multiple myeloma cell growth in vitro and in vivo
Teru Hideshima et al.
CLINICAL CANCER RESEARCH (2006)
PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum
Stephen S. Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Proteasome inhibitors induce death but activate NF-κB on endometrial carcinoma cell lines and primary culture explants
Xavier Dolcet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment
Yu-Tzu Tai et al.
CANCER RESEARCH (2006)
Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ
Kumiko Nagashima et al.
BLOOD (2006)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Teru Hideshima et al.
BLOOD (2006)
A selective small molecule I kappa B kinase beta inhibitor blocks nuclear factor kappa B- mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells
Danyi Wen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
NFκB:: Linking inflammation and immunity to cancer development and progression
M Karin et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A novel NF-κB pathway involving IKKβ and p65/Re1A ser-536 phosphorylation results in p53 inhibition in the absence of 1NF-κB transcriptional activity
SJ Jeong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A mechanistic insight into a proteasome-independent constitutive inhibitor κBα (IκBα) degradation and nuclear factor κB (NF-κB) activation pathway in WEHI-231 B-cells
SD Shumway et al.
BIOCHEMICAL JOURNAL (2004)
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma
T Hideshima et al.
ONCOGENE (2003)
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571
CR Yu et al.
BLOOD (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
CD40 induces human multiple myeloma. cell migration via phosphatidylinositol 3-kinase/AKT/NF-κB signaling
YT Tai et al.
BLOOD (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice
JR Burke et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
RZ Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
N Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells:: therapeutic implications
CS Mitsiades et al.
ONCOGENE (2002)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma:: therapeutic applications
T Hideshima et al.
ONCOGENE (2001)